Here, a phase II trial was performed to explore the safety and efficacy of apatinib combined with camrelizumab in advanced acral melanoma patients as first-line therapy (NCT03955354)….The TMB High rates were 80.0% (4/5) versus 38.4% (5/13) in Re group versus un Re group. According to survival status, a gene set containing TTN, MUC16, VPS13D, ALPK2 and SCUBE1 was established, which was considered positive when at least one gene was altered (Table 3). Patients with gene-set positive showed markedly better PFS and OS than those with gene-set negative in this cohort